RT Journal Article
T1 Conversion From Immediate-Release Tacrolimus to Prolonged-Release Tacrolimus in Stable Heart Transplant Patients: A Retrospective Study.
A1 González-Vílchez, Francisco
A1 Delgado, Juan F
A1 Palomo, Jesús
A1 Mirabet, Sonia
A1 Díaz-Molina, Beatriz
A1 Almenar, Luis
A1 Arizón, José M
A1 Rangel-Sousa, Diego
A1 Pérez-Villa, Félix
A1 Garrido, Iris P
A1 de la Fuente, Luis
A1 Gómez-Bueno, Manuel
A1 Sanz, María L
A1 Crespo-Leiro, María G
AB Lifelong adherence with post-transplant immunosuppression is challenging, with nonadherence associated with greater acute rejection (AR) risk. This retrospective study evaluated conversion from immediate-release tacrolimus (IRT) to prolonged-release tacrolimus (PRT), between January 2008 and December 2012 in stable adult heart transplant recipients. Cumulative incidence rate (IR) of AR and infection pre- and postconversion, safety, tacrolimus dose and trough levels, concomitant immunosuppression, and PRT discontinuation were analyzed (intention-to-treat population). Overall, 467 patients (mean age, 59.3 [SD, 13.3] years) converted to PRT at 5.1 (SD, 4.9) years post transplant and were followed for 3.4 (SD, 1.5) years. During the 6 months post conversion, 5 patients (1.1%; 95% CI, 0.35%-2.48%) had an AR episode and IR was 2.2/100 patient-years (95% CI, 0.91-5.26). Incidence of rejection preconversion varied by time from transplant to conversion. Infection IR was similar post- and preconversion (9.2/100 patient-years [95% CI, 7.4-11.3] vs 10.6/100 patient-years [95% CI, 8.8-12.3], respectively; P = .20). Safety variables remained similar post conversion. The IR of mortality/graft loss was 2.3/100 patient-years (95% CI, 1.7-3.1). Conversion from IRT to PRT in heart transplant recipients in Spain was associated with no new safety concerns and appropriate immunosuppressive effectiveness.
YR 2019
FD 2019-06-18
LK http://hdl.handle.net/10668/14155
UL http://hdl.handle.net/10668/14155
LA en
DS RISalud
RD Apr 10, 2025